We can’t show the full text here under this license. Use the link below to read it at the source.
Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
Heart health in type 2 diabetes patients treated with SGLT-2 inhibitors compared to GLP-1 receptor agonists in everyday care
AI simplified
Abstract
T2D patients treated with SGLT2 inhibitors experienced a lower rate of major adverse cardiovascular events compared to those treated with GLP-1 receptor agonists.
- The study involved 8596 matched T2D patients over a median follow-up of 13 months.
- SGLT2 inhibitor treatment was associated with a hazard ratio (HR) of 0.68 for major adverse cardiovascular events, indicating a reduced risk compared to GLP-1 receptor agonists.
- Myocardial infarction rates were lower in the SGLT2i group, with an HR of 0.72.
- Hospitalization for heart failure was reduced in SGLT2i patients, showing an HR of 0.59.
- Hospitalization for cardiovascular causes was also lower in the SGLT2i group, with an HR of 0.82.
- No significant differences in adverse events were observed between the two treatment groups.
AI simplified
Key numbers
0.68
3P-MACE Rate Reduction
Hazard Ratio for SGLT2i vs. GLP-1RA
0.59
Heart Failure Hospitalization Rate Reduction
Hazard Ratio for SGLT2i vs. GLP-1RA
0.72
Myocardial Infarction Rate Reduction
Hazard Ratio for SGLT2i vs. GLP-1RA